about
Management of patients with hepatitis B who require immunosuppressive therapySurvival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantationHepatitis C virus screening in patients with cancer receiving chemotherapy.Medical care of hepatitis B among Asian American populations: perspectives from three provider groups.Hepatitis B virus management to prevent reactivation after chemotherapy: a review.AASLD guidelines for treatment of chronic hepatitis B.Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.Improving wait time for chemotherapy in an outpatient clinic at a comprehensive cancer centerHepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patientsHIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.Low rates of hepatitis B virus screening at the onset of chemotherapy.Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver DiseasesHepatic stem cells and transforming growth factor β in hepatocellular carcinomaWide variation in content of inpatient do-not-resuscitate order forms used at National Cancer Institute-designated cancer centers in the United States.Human papillomavirus knowledge and awareness among Vietnamese mothers.Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study.Attitudes toward hepatitis B virus among Vietnamese, Chinese and Korean Americans in the Houston area, Texas.Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.Accuracy of reporting current medications by cancer patients presenting to an emergency center.Impact of hepatitis E virus seropositivity on chronic liver disease in cancer patients with hepatitis C virus infection.Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients.Acculturation, body perception, and weight status among Vietnamese American students.Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant.Challenges in outpatient end-of-life care: wishes to avoid resuscitation.Hematopoietic stem cell transplantation among patients with leukemia of all ages in Texas.Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.Reply to J. Cabezas et al.Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.Universal screening for hepatitis C: A needed approach in patients with haematologic malignancies.Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart reviewHepatitis B virus and hepatitis C virus infection in immunocompromised patientsHepatitis B and hepatitis C prevalence and treatment referral among Asian Americans undergoing community-based hepatitis screeningReplyPrevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United StatesCost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer TherapyHepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib
P50
Q26853490-4188AF91-4671-45AD-8362-1E12463F613AQ33405646-921EF3B8-62D8-441B-B47E-2DC0871AE62EQ33600085-9D174484-A831-4312-88CF-D187B13D5DE4Q33730890-129A0274-43EA-4BE0-B1A9-2D269C0A2555Q34397738-A05C67CD-EB63-4330-BF97-C82C557FB6B7Q34501660-89B9DA8D-1E73-46B6-9064-1FE857C49524Q35037621-ADBD17B9-4576-4CAB-BEF4-A35214699559Q35695932-D17E3A66-A091-47BB-96EB-02F6F8F738F5Q35771194-EB285FEB-96D3-4D5E-B037-A2D357AA7101Q35878321-4739F072-C92F-48A4-B934-D88F5B31AEEAQ36073717-08A7F763-F76D-486A-9C3C-CA2B9BFFAECAQ36095262-E7848792-950A-4BE8-AA79-E7097B055189Q36803202-9668E6A0-3BA1-4B77-B127-57EAB46A3C68Q37099380-210996BE-DF4B-4218-8869-5BBF4FE44CD4Q37235967-EA662F33-CE4B-4667-87CF-3A0B321C7957Q37297132-9B8333E8-F07F-48EF-B01D-EF5D6AB2CB71Q37341258-5A8F5568-716E-4DF4-A984-1CBC52115E1CQ37720515-D8BE54A0-8353-4A00-8CE7-89CB05C34509Q38778109-67FD5F27-B7F0-4060-BA40-DAD1080C4DC6Q39937741-F72CCAF2-2537-4213-BBC9-B96904EF4816Q41609788-334B1958-132F-4964-907F-1E405C19FF0BQ41727579-48D03C34-5FEA-4CE8-A4D6-57FA6C0B45ACQ42983064-01A2D3C9-F5FF-44FC-A44F-D624F1A82F1FQ47306314-2FE01657-0135-4E8C-AC98-2219083DF1CFQ47707048-D3F43EB4-BA4A-4DC1-ADA2-31C49B4468A6Q47896216-EAD9FF29-A534-4D31-98BE-98D61E50AEC3Q48607817-CB901622-D775-4E14-9B63-FBCE89E8D1D6Q50190669-D97D7996-128C-44B6-8D81-895EEAB11E03Q50928237-1734BACD-81CE-49EB-8EAD-8A78B06232B7Q52558652-4D19E953-F52D-4F63-9487-0FA8D34E9608Q54235088-391FF94B-9722-4801-B9AB-39E5C9C388FEQ57058824-47E79915-01A3-4095-AE7D-EDC7C3FBE2F3Q57296843-AD66B823-B1F9-4AFA-9201-1F62A4D9B3A0Q82859818-BA2F79ED-FA93-4322-8526-53D87CF5A066Q90709899-5993D6C2-8DC5-417E-856F-496052331DC1Q90828662-044F45A1-2E6D-4C7F-8910-5532FBDA1501Q92502172-EF889835-6E96-4652-A87D-5CBC04FB0DB2Q92607562-111599E1-024C-483F-8E87-4C41693085B9
P50
description
researcher ORCID ID = 0000-0002-5896-4182
@en
wetenschapper
@nl
name
Jessica P Hwang
@ast
Jessica P Hwang
@en
Jessica P Hwang
@es
Jessica P Hwang
@nl
type
label
Jessica P Hwang
@ast
Jessica P Hwang
@en
Jessica P Hwang
@es
Jessica P Hwang
@nl
prefLabel
Jessica P Hwang
@ast
Jessica P Hwang
@en
Jessica P Hwang
@es
Jessica P Hwang
@nl
P106
P1153
8648532300
P21
P31
P496
0000-0002-5896-4182